- Zai Lab Limited (ZLAB, Financial) is presenting promising data at the AACR 2025 on two innovative oncology therapies, ZL-6201 and ZL-1222.
- ZL-6201 is advancing into Investigational New Drug studies in 2025 as a potential first-in-class ADC treatment for LRRC15-positive solid tumors.
- ZL-1222, a novel anti-PD-1/IL-12 immunocytokine, shows potent anti-tumor activity with improved systemic safety compared to existing treatments.
Zai Lab Limited (ZLAB), a leading biopharmaceutical company, is showcasing new data from the evaluation of two pioneering oncology therapies, ZL-6201 and ZL-1222, at the American Association for Cancer Research (AACR) Annual Meeting 2025 held in Chicago, Illinois. The findings suggest substantial potential for these therapies in expanding treatment options across a range of cancer types.
ZL-6201 is an investigational leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) designed with the TMALIN® platform. This platform maximizes tumor microenvironment interactions to overcome limitations of first-generation ADCs, notably off-target toxicity. The preclinical data indicates that ZL-6201 internalizes effectively within tumor cells, facilitating tumor growth suppression in multiple models. This has paved the way for its progression into IND-enabling studies targeting LRRC15-positive solid tumors, including sarcoma, breast cancer, and others, in 2025.
Additionally, ZL-1222 is being explored for its dual mechanism of action targeting the PD-1/PD-L1 signaling pathway while activating T cells via IL-12. The therapy demonstrates significant anti-tumor activity with a favorable safety profile compared to traditional systemic IL-12 therapies. The research findings are particularly promising for patients with tumors resistant to conventional immune checkpoint inhibitors.
"These advancements in our oncology portfolio underscore our commitment to addressing the limitations of existing cancer therapies and offering innovative treatment avenues," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. The company, through its robust research initiatives, continues to aim for groundbreaking therapeutics to enhance patient outcomes globally.
